NCT07101094 - Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU) | Biotech Hunter

Enrollment

300

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 30, 2029

Study Completion Date

March 30, 2029

Conditions

Schizophrenia

Interventions

DRUG

xanomeline and trospium chloride (X/T) therapy

According to the product label

Trial Locations (8)

Local Institution - 0004, Catonsville

Local Institution - 0007, Baltimore

Local Institution - 0006, Fort Mill

Local Institution - 0003, Evanston

Local Institution - 0005, Omaha

Omaha Insomnia and Psychiatric Services, Omaha

Local Institution - 0002, Boston

Local Institution - 0001, Belle Mead